ストックスクリーナーアプリを入手
5.22
0.77%
0.04
アフターアワーズ：
5.30
0.08
+1.53%
Vanda Pharmaceuticals Inc (VNDA) 最新ニュース
Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
VNDA|Vanda Pharmaceuticals Inc|Price:5.280|Chg%:+0.100 - TradingKey
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
VNDA|Vanda Pharmaceuticals Inc|Price:5.280|Chg%:-0.080 - TradingKey
Vanda's NDA Rejection Challenge Can't Be Heard At DC Court - Law360
ETFs Investing in Vanda Pharmaceuticals Inc. Stocks - TradingView
Licensable picture: Vanda Pharmaceuticals Athens OpenDay 5 - reutersconnect.com
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Vanda PharmaceuticalsRisks Rising, Rewards DwindlingWhy I'm Downgrading To Hold - Seeking Alpha
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular PsoriasisA Milestone Recognition of GPP as a Distinct Rare Disease in Europe - Sahm
Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP - TradingView
Vanda Pharmaceuticals (VNDA) Receives Orphan Drug Designation fo - GuruFocus
EMA Panel Recommends First EU Orphan Designation for Rare Skin Disease - Stock Titan
Vanda shifts Nereus marketing into high gear with Schumacher IndyCar sponsorship - Fierce Pharma
Insider Sellers Might Regret Selling Vanda Pharmaceuticals Shares at a Lower Price Than Current Market Value - simplywall.st
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment - Sahm
Vanda Pharmaceuticals Athens OpenDay 4 - reutersconnect.com
NEREUStm Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment - Lelezard
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrati - GuruFocus
Vanda Pharma's new motion sickness drug NEREUS™... - Pluang
IndyCar News: Vanda Pharmaceuticals Sponsor Schumacher for Four Races - AutoRacing1.com
Has Vanda Pharmaceuticals Finally Found Its Game-Changer with Bysanti - Kavout | AI
Vanda Pharmaceuticals to be Primary Sponsor of Mick Schumacher’s INDYCAR Entry for Four Races Beginning in Nashville This Weekend - Catchfence
Vanda Pharmaceuticals To Be Primary Sponsor Of Schumacher’s INDYCAR Entry For Four Races; Schumacher to Pilot the No. 47 NEREUS™ Honda at events in Nashville, Portland, Washington D.C. and Monterey - Rahal Letterman Lanigan
47 years since the last new motion-sickness treatment, NEREUS will sponsor IndyCar - Stock Titan
Judge Says Vanda-FDA Appointments Fight Likely Ripe - Law360
Vanda Fights to Sway Court to Keep Suit Over FDA’s Drug Reviews - Bloomberg Law News
Daniel Patrick Mcguire Net Worth (2026) - GuruFocus
Vanda Pharmaceuticals (VNDA) Slides 3.85% as Stock Tests Key Support at $5.7TICK Divergence - DonanımHaber
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
Vanda Pharmaceuticals to join B. Riley Summit f... - Pluang
Vanda Pharmaceuticals plans fireside chat at Boston investor summit - Stock Titan
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit - PR Newswire
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on FDA designation By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on FDA designation - Investing.com India
Vanda’s antisense therapy wins FDA rare pediatric disease designation for CMT2S - AllSci
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Desig - GuruFocus
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits
Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation - GuruFocus
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S - Quantisnow
Vanda Pharmaceuticals updates investors on business outlook as shares trade in the U.S. market - ad-hoc-news.de
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits
VNDAVanda Pharmaceuticals Inc Volatility & Greeks - Finviz
McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY® - McDermott Will & Schulte
Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA) - Yahoo Finance
Vanda Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- McGuire Daniel Patrick - Moomoo
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index - marketscreener.com
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):